The impact of market volatility on the cell therapy industry

Cell Stem Cell

Volumn 9, Issue 5, 2011, Pages 397-401

  Brindley, David A ^a,b,c,g   Reeve, Brock C ^b   Sahlman, William A ^c   Bonfiglio, Greg A ^d,e   Davie, Natasha L ^a,b,f,g   Culme Seymour, Emily J ^g   Mason, Chris ^a,g  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c HARVARD BUSINESS SCHOOL   (United States)

^d Proteus Venture Partners   (United States)

^e Centre for Commercialization of Regenerative Medicine   (Canada)

^f HARVARD MEDICAL SCHOOL   (United States)

^g London Regenerative Medicine Network   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY; FUNDING; HEALTH CARE INDUSTRY; MARKET; PRIORITY JOURNAL; REVIEW;

EID: 80755174403     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2011.10.010     Document Type: Note

References (9)

1. C.M. Christensen, R. Bohmer, and J. Kenagy Harv. Bus. Rev. 2000 (September-October): 2000
2. Cooksey, D. 2006. Review of UK Healthcare Research Funding, HM Treasury (ed.). (London, UK: St Clements House).
3. J. Fenn, and M. Raskino Mastering the Hype Cycle: How to Choose the Right Innovation at the Right Time 2008 Harvard Business School Press Boston
4. C. Mason Regen. Med. 2 2007 11 18
5. C. Mason, and E. Manzotti Regen. Med. 5 2010 153 155
6. C. Mason, D.A. Brindley, E.J. Culme-Seymour, and N.L. Davie Regen. Med. 6 2011 265 272
7. R. McKernan, J. McNeish, and D. Smith Cell Stem Cell 6 2010 517 520
8. M.S. Rao Cell Stem Cell 9 2011 7 10
9. W.A. Sahlman, and H.H. Stevenson J. Bus. Venturing 1 1985 7 30